Cited 0 times in
Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, HJ | - |
dc.contributor.author | Lee, PH | - |
dc.contributor.author | Bang, OY | - |
dc.contributor.author | Lee, G | - |
dc.contributor.author | Ahn, YH | - |
dc.date.accessioned | 2011-01-14T05:35:01Z | - |
dc.date.available | 2011-01-14T05:35:01Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0022-3042 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/1153 | - |
dc.description.abstract | Parkinson's disease is a common progressive neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. We investigated whether cell therapy with human mesenchymal stem cells (hMSCs) had a protective effect on progressive dopaminergic neuronal loss in vitro and in vivo. In primary mesencephalic cultures, hMSCs treatment significantly decreased MG-132-induced dopaminergic neuronal loss with a significant reduction of caspase-3 activity. In rats received systemic injection of MG-132, hMSCs treatment in MG-132-treated rats dramatically reduced the decline in the number of tyrosine hydroxylase (TH)-immunoreactive cells, showing an approximately 50% increase in the survival of TH-immunoreactive cells in the substantia nigra compared with the MG-132-treated group. Additionally, hMSC treatment significantly decreased OX-6 immunoreactivity and caspase-3 activity. Histological analysis showed that the number of NuMA-positive cells was 1.7% of total injected hMSCs and 35.7% of these cells were double-stained with NuMA and TH. Adhesive-removal test showed that hMSCs administration in MG-132-treated rats had a tendency to decrease in the mean removal time. This study demonstrates that hMSCs treatment had a protective effect on progressive loss of dopaminergic neurons induced by MG-132 in vitro and in vivo. Complex mechanisms mediated by trophic effects of hMSCs and differentiation of hMSCs into functional TH-immunoreactive neurons may work in the neuroprotective process. | - |
dc.language.iso | en | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Caspase 3 | - |
dc.subject.MESH | Cell Communication | - |
dc.subject.MESH | Cell Count | - |
dc.subject.MESH | Cell Death | - |
dc.subject.MESH | Cell Differentiation | - |
dc.subject.MESH | Cell Survival | - |
dc.subject.MESH | Cysteine Proteinase Inhibitors | - |
dc.subject.MESH | Cytoprotection | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Dopamine | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leupeptins | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mesenchymal Stem Cell Transplantation | - |
dc.subject.MESH | Mesenchymal Stem Cells | - |
dc.subject.MESH | Nerve Growth Factors | - |
dc.subject.MESH | Neurons | - |
dc.subject.MESH | Parkinsonian Disorders | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Substantia Nigra | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tyrosine 3-Monooxygenase | - |
dc.title | Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. | - |
dc.type | Article | - |
dc.identifier.pmid | 18665911 | - |
dc.contributor.affiliatedAuthor | 이, 광 | - |
dc.contributor.affiliatedAuthor | 안, 영환 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1111/j.1471-4159.2008.05589.x | - |
dc.citation.title | Journal of neurochemistry | - |
dc.citation.volume | 107 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2008 | - |
dc.citation.startPage | 141 | - |
dc.citation.endPage | 151 | - |
dc.identifier.bibliographicCitation | Journal of neurochemistry, 107(1). : 141-151, 2008 | - |
dc.identifier.eissn | 1471-4159 | - |
dc.relation.journalid | J000223042 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.